Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00096525 · ClinicalTrials.gov registry record · Phase 2
Lenalidomide in Treating Patients With Advanced or Unresectable Kidney Cancer
A Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00096525: Completed Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00096525 is a Phase 2 study that has completed, run by Memorial Sloan Kettering Cancer Center. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00096525, a Phase 2 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Biological therapy such as lenalidomide use different ways to stimulate the immune system and stop tumor cells from growing. It may also stop the growth of tumor cells by stopping blood flow to the tumor. PURPOSE: This phase II trial is studying how well lenalidomide works in treating patients with advanced or unresectable kidney cancer.
Interventions
- DRUG lenalidomide
Trial Details
| Field | Value |
|---|---|
| Start Date | 2004-07 |
| Phase | Phase 2 |
What the finished NCT00096525 record still lists
NCT00096525 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which lenalidomide is the first listed.
NCT00096525 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00096525 about?
NCT00096525 is a clinical study titled "Lenalidomide in Treating Patients With Advanced or Unresectable Kidney Cancer". RATIONALE: Biological therapy such as lenalidomide use different ways to stimulate the immune system and stop tumor cells from growing. It may also stop the growth of tumor cells by stopping blood flow to the tumor. PURPOSE: This phase II trial is studying how well lenalidomide works in treating pa...
What is the current status of trial NCT00096525?
This trial is currently completed. It is a Phase 2 study. The study started on 2004-07.
What interventions are being tested in trial NCT00096525?
The interventions under investigation include: lenalidomide (DRUG).
Who is sponsoring clinical trial NCT00096525?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia